M William Audeh, MD

IM/Hematology/Oncology

Office: 310-423-1188Available 24/7: 1-800-CEDARS-1
  • SPECIALTY
  • CLINICAL AREAS
  • PROVIDER INFO
  • EDUCATION
  • AFFILIATIONS
  • RESEARCH & PUBLICATIONS
  • ACHIEVEMENTS

Office location

Cedars-Sinai Medical Center
3104231188
8700 Beverly Blvd. Samuel Oschin Comprehensive Cancer Institute
Los Angeles
CA
90048

Specialty

  • IM/Hematology/Oncology

    Clinical Areas

    • BRCA (Mutation, Positive, Carrier)
    • BRCA Testing (Breast and Ovarian Cancer Gene)
    • Breast Cancer Risk Assessment and Risk Reduction
    • Breast Cancers
    • Cancer Genetics

    Provider Info

    GENDER

    Male

    LANGUAGES

    English

    EXPERIENCE

    37 years

    Education

    • Carleton College
      Undergraduate - Completed 1977
    • Stanford Medical Center
      Residency - Completed 1986
    • Stanford Medical Center
      Fellowship - Completed 1989
    • University of Iowa
      Medical School - Completed 1982
    • University of Minnesota
      Master - Completed 1978

    Research

    M. William Audeh, MD, specializes in the treatment and prevention of breast cancer, and conducts clinical and translational research related to these areas. His work uses molecular profiling of breast cancers to determine personalized treatment strategies with targeted therapies, clinical trials with molecularly targeted therapies, and genetically targeted therapies such as PARP inhibitors against cancers with DNA repair defects, such as BRCA-mutated cancers. Breast cancer risk reduction is based on personalized risk assessment (genetics, hormonal and exposure history, diagnostic testing, etc.) and appropriate interventions.

    PUBLICATIONS

    • Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med. 2014;7:307-316.
    • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
    • Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
    • Audeh, MW. Genetic Predisposition to Cancer – Malfunction or Maladaptation?. Horizons in Cancer Therapeutics –From Bench to Bedside. 2003;4:3-18.

    Achievements

    Board Certifications

    • Board Certified in Internal Medicine
    • Board Certified in Medical Oncology

    Awards & Activities

    • Member, American Society of Human Genetics - 1995-present
    • Member, American Association of Cancer Research - 1989-present
    • Member, American Society of Clinical Oncology - 1986-present
    • American Cancer Society Clinical Fellowship in Oncology - 1986-87
    more